Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer
Ciuleanu, Tudor-Eliade, Ahmed, Samreen, Kim, Joo-Hang, Mezger, Jörg, Park, Keunchil, Thomas, Michael, Chen, Jihong, Poondru, Srinivasu, VanTornout, Jan M, Whitcomb, Debbie, Blackhall, Fiona
Published in British journal of cancer (05.09.2017)
Published in British journal of cancer (05.09.2017)
Get full text
Journal Article
P2.06-021 Efficacy and Safety of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment in Subjects with EGFRMut+ NSCLC
Kelly, Ronan, Horn, Leora, Chih-Hsin Yang, James, Lee, Dae Ho, Desai, Bhardwaj, Fleege, Tanya, Jie, Fei, Poondru, Srinivasu, Keating, Anne, Whitcomb, Debbie, Murase, Tosei, Uegaki, Koichi, Aoyama, Kouji, Nakagawa, Kazuhiko
Published in Journal of thoracic oncology (01.01.2017)
Published in Journal of thoracic oncology (01.01.2017)
Get full text
Journal Article
P2.06-021 Efficacy and Safety of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment in Subjects with EGFRMut+ NSCLC: Topic: Phase III
Kelly, Ronan, Horn, Leora, Chih-Hsin Yang, James, Lee, Dae Ho, Desai, Bhardwaj, Fleege, Tanya, Jie, Fei, Poondru, Srinivasu, Keating, Anne, Whitcomb, Debbie, Murase, Tosei, Uegaki, Koichi, Aoyama, Kouji, Nakagawa, Kazuhiko
Published in Journal of thoracic oncology (01.01.2017)
Published in Journal of thoracic oncology (01.01.2017)
Get full text
Journal Article
Abstract A47: Clinical profile of ASP8273, a mutant-selective EGFR inhibitor, in subjects with EGFR-mutation positive non-small cell lung cancer: interim results from an ongoing, phase 1, open-label, dose-escalation study
Yu, Helena, Oxnard, Geoffrey R., Spira, Alexander, Horn, Leora, Weiss, Jared, Feng, Yan, West, Howard, Giaccone, Giuseppe, Evans, Tracey, Kelly, Ronan, Fleege, Tanya, Poondru, Srinivasu, Jie, Fei, Aoyama, Kouji, Whitcomb, Debbie, Keating, Anne, Krivoshik, Andrew
Published in Molecular cancer therapeutics (01.12.2015)
Published in Molecular cancer therapeutics (01.12.2015)
Get full text
Journal Article
Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study
Yu, Helena Alexandra, Spira, Alexander I., Horn, Leora, Weiss, Jared, West, Howard Jack, Giaccone, Giuseppe, Evans, Tracey L., Kelly, Ronan Joseph, Desai, Bhardwaj B., Krivoshik, Andrew, Fleege, Tanya E., Poondru, Srinivasu, Jie, Fei, Aoyama, Kouji, Whitcomb, Debbie Ann, Keating, Anne Therese, Oxnard, Geoffrey R.
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC
Yu, Helena Alexandra, Oxnard, Geoffrey R., Spira, Alexander I., Horn, Leora, Weiss, Jared, Feng, Yan, West, Howard Jack, Giaccone, Giuseppe, Evans, Tracey L., Kelly, Ronan Joseph, Fleege, Tanya, Poondru, Srinivasu, Jie, Fei, Aoyama, Koji, Foley, Margaret A., Whitcomb, Debbie, Keating, Anne Therese, Krivoshik, Andrew P.
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article